首页> 外文期刊>Frontiers in Cell and Developmental Biology >Reveal the Regulation Patterns of Prognosis-Related miRNAs and lncRNAs Across Solid Tumors in the Cancer Genome Atlas
【24h】

Reveal the Regulation Patterns of Prognosis-Related miRNAs and lncRNAs Across Solid Tumors in the Cancer Genome Atlas

机译:揭示癌症基因组地图集的实体瘤中预后相关的miRNA和LNCRNA的调节模式

获取原文
       

摘要

Background: The dysregulation of noncoding RNAs (ncRNAs) such as miRNAs and lncRNAs are associated with the pathogenesis and progression in multiple cancers including solid tumors. Comprehensive investigations of prognosis-related ncRNA markers could promote the development of therapeutic strategies for solid tumors, but rarely reported. Methods: By taking advantage of The Cancer Genome Atlas (TCGA), pan-cancer prognosis analysis (PCPA) models were firstly constructed based on miRNA and lncRNA expression profiles of 8,450 samples in 19 solid tumors. Further, the co-occurrence and exclusivity among ncRNA markers were systematically analyzed for different cancers. Results: In identified ncRNA makers, 71% of the miRNA markers were shared in multiple cancers, whereas 96% of the lncRNA markers were cancer-specific. Moreover, to analyze the regulation patterns of prognosis-related ncRNAs at the pan-cancer level, miRNA markers were further annotated into 8 carcinogenic pathways. Results represented that approximately 86% of these miRNA markers could regulate the PI3K-Akt signaling pathway, while only 48% for the Notch signaling pathway. Finally, among 126 common genes that participated in 8 carcinogenic pathways, BCL2, CSNK2A1, EGFR, PDGFRA, and VEGFA were proposed as potential drug targets for multiple cancers. Conclusions: The prognosis analysis and regulation characteristics of ncRNAs presented in this study may help to facilitate the discovery of anti-cancer drugs for multiple solid tumors.
机译:背景:诸如miRNA和LNCRNA的非沉积RNA(NCRNA)的失调与包括固体瘤的多种癌症的发病机制和进展相关。综合研究预后相关的NCRNA标记可以促进实体肿瘤的治疗策略的发展,但很少报道。方法:通过利用癌症基因组地图集(​​TCGA),首先基于MiRNA和LNCRNA表达分布在19个实体瘤中的8,450个样品的MiRNA和LncrNA表达谱来构建泛癌预后分析(PCPA)模型。此外,对不同的癌症系统地分析了NCRNA标记物之间的共发育和排他性。结果:在鉴定的NCRNA制造商中,71%的miRNA标记在多种癌症中共用,而96%的LNCRNA标记物是癌症特异性的。此外,为了分析泛癌水平的预后相关NCRNA的调节模式,MiRNA标记物进一步注释为8个致癌途径。结果表明,这些MiRNA标记的约86%可以调节PI3K-AKT信号通路,而陷波信号通路仅为48%。最后,在参与8个致癌途径的126个常见基因中,提出了BCL2,CSNK2A1,EGFR,PDGFRA和VEGFA作为多种癌症的潜在药物靶标。结论:本研究中呈现的NCRNA的预后分析和调节特征可有助于促进对多种实体瘤的抗癌药物的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号